Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also presents ...

A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S. Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM ...